Xenon Pharmaceuticals surges 43.6% as Phase 3 azetukalner epilepsy data beats expectations

Xenon Pharmaceuticals (XENE) is up 43.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears driven by Xenon’s positive Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures, which showed strong efficacy versus placebo and a tolerability profile consistent with prior studies. Investors also likely reacted to the clearer regulatory path, as the company reiterated plans to submit an FDA NDA in Q3 2026.

Details:

Xenon reported X-TOLE2 met its primary endpoint, with the 25 mg dose showing a -53.2% median percent change in monthly focal onset seizure frequency versus -10.4% for placebo over 12 weeks.

The company highlighted a placebo-adjusted effect of -42.7% for the 25 mg arm, which it said outperformed its earlier Phase 2b X-TOLE study on the same endpoint.

Key secondary endpoint results were also positive: the RR50 responder rate was 54.8% for 25 mg versus 20.8% for placebo.

This could be because stronger-than-expected pivotal data may prompt investors to model higher adoption and/or improved pricing power for a differentiated epilepsy option, ahead of a planned NDA submission timeline.

Sources:

SEC, GlobeNewswire, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$XENE Insider Trading Activity

$XENE insiders have traded $XENE stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:

IAN MORTIMER (PRESIDENT & CEO) has made 0 purchases and 7 sales selling 90,302 shares for an estimated $3,927,972.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$XENE Hedge Fund Activity

We have seen 127 institutional investors add shares of $XENE stock to their portfolio, and 113 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BRAIDWELL LP removed 1,779,953 shares (-49.4%) from their portfolio in Q4 2025, for an estimated $79,777,493
WELLINGTON MANAGEMENT GROUP LLP added 1,154,922 shares (+32.0%) to their portfolio in Q4 2025, for an estimated $51,763,604
COMMODORE CAPITAL LP removed 900,000 shares (-33.3%) from their portfolio in Q4 2025, for an estimated $40,338,000
DEEP TRACK CAPITAL, LP removed 833,565 shares (-69.5%) from their portfolio in Q4 2025, for an estimated $37,360,383
PRICE T ROWE ASSOCIATES INC /MD/ added 820,608 shares (+1968.3%) to their portfolio in Q4 2025, for an estimated $36,779,650
MILLENNIUM MANAGEMENT LLC removed 748,951 shares (-54.1%) from their portfolio in Q4 2025, for an estimated $33,567,983
HOLOCENE ADVISORS, LP removed 694,472 shares (-35.1%) from their portfolio in Q4 2025, for an estimated $31,126,235

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$XENE Analyst Ratings

Wall Street analysts have issued reports on $XENE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 11/18/2025
Needham issued a "Buy" rating on 11/04/2025
RBC Capital issued a "Outperform" rating on 11/04/2025
Chardan Capital issued a "Buy" rating on 10/07/2025

To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.

$XENE Price Targets

Multiple analysts have issued price targets for $XENE recently. We have seen 6 analysts offer price targets for $XENE in the last 6 months, with a median target of $58.0.

Here are some recent targets:

Serge Belanger from Needham set a target price of $58.0 on 02/27/2026
Benjamin Burnett from Wells Fargo set a target price of $49.0 on 02/27/2026
Rudy Li from Wolfe Research set a target price of $60.0 on 02/24/2026
Tessa Romero from JP Morgan set a target price of $62.0 on 01/09/2026
Brian Abrahams from RBC Capital set a target price of $58.0 on 11/04/2025
Rudy Li from Chardan Capital set a target price of $55.0 on 10/07/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.